Origenis is at the forefront of drug discovery, utilizing advanced artificial intelligence (AI) technologies to develop small molecule drug pipelines aimed at addressing unmet medical needs, particularly in oncology and neurology. Their innovative approach replaces traditional drug discovery methods by employing an AI-driven platform that integrates in silico design with efficient wet lab realization. This platform enables the identification and optimization of novel compounds that can effectively penetrate difficult-to-reach tissues, such as the brain and the eye. Key technologies like BRAINstorm™ and EYEdeal™ are specifically designed to overcome biological barriers, ensuring that their small molecule drugs achieve high potency and selectivity at their target sites.

The company’s drug pipeline focuses on a variety of therapeutic areas, including neurodegeneration, brain cancer, and viral infections. Origenis is developing highly selective protein kinase inhibitors and protease inhibitors that target the underlying causes of diseases like Parkinson's and Alzheimer's. Their research also extends to creating small molecule antivirals optimized for brain penetration, addressing the challenges posed by viral infections. By leveraging synergies in disease mechanisms and molecular targets, Origenis aims to redefine treatment standards and improve patient outcomes through their cutting-edge drug development strategies.

Germany

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

Origenis

Company Details